Evidence map›Paper›PMID 40666859›Full record

ArticlebioRxiv : the preprint server for biology2025

Virus glycoprotein nanodisc platform for vaccine design.

Kimmo Rantalainen, Alessia Liguori, Gabriel Ozorowski, Claudia Flynn, Jon M Steichen, Olivia Swanson, Patrick J Madden, Sabyasachi Baboo, Swastik Phulera, Anant Gharpure and 23 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Kimmo RantalainenDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-3158-9183
Alessia LiguoriDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Gabriel OzorowskiConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Claudia FlynnDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Jon M SteichenDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Olivia SwansonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-8162-8358
Patrick J MaddenConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Sabyasachi BabooDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-4547-5160
Swastik PhuleraDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-1272-7712
Anant GharpureDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Danny LuDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Oleksandr KalyuzhniyDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Patrick SkogDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Sierra TeradaDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Monolina ShilConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Jolene K DiedrichDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Erik GeorgesonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Ryan TingleDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Saman EskandarzadehDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Wen-Hsin LeeDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Nushin AlaviDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Diana GoodwinDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Michael KubitzDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Sonya AmirzehniDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Sunny HimansuModerna Inc., Cambridge, MA, 02139, USA.
Devin SokDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Jeong Hyun LeeDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
John R YatesDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
James C PaulsonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Shane CrottyConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-6484-6262
Torben SchiffnerDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Andrew B WardConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-7153-3769
William R SchiefDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Design and testing of immunogens to elicit 10E8-like broadly neutralizing antibodies against HIVR01AI147826 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SCHIFFNER, TORBEN · 2019 to 2025
$8.0M
Gates Foundation INV-002916Gates Foundation INV-007522Gates Foundation INV-008813NIAID NIH HHS R01 AI147826NIAID NIH HHS UM1 AI144462
6 · The paper itself

Abstract

Transmembrane glycoproteins of enveloped viruses are the targets of neutralizing antibodies and essential vaccine antigens. mRNA-LNP technology allows in situ production of transmembrane glycoproteins upon immunization, but biophysical characterization of transmembrane antigens and in vitro analysis of post-immunization antibody responses typically rely on soluble proteins. Here, we present a methodological platform for assembling transmembrane glycoprotein vaccine candidates into lipid nanodiscs. We demonstrate the utility of the nanodiscs in HIV membrane proximal external region (MPER)-targeting vaccine development by binding assays using surface plasmon resonance (SPR), ex vivo B cell sorting with fluorescence-activated cell sorting (FACS), and by determining the structure of a prototypical HIV MPER-targeting immunogen nanodisc in complex with three broadly neutralizing antibodies (bnAbs), including the MPER bnAb 10E8, to 3.5 Å by cryogenic electron microscopy (cryo-EM), providing a template for structure-based immunogen design for MPER. Overall, the platform offers a tool for accelerating the development of next-generation viral vaccines.

Identifiers

PMID40666859
PMCPMC12262266

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.